British Researchers Test First AI-Designed Universal Vaccine in Humans

British researchers have completed the first human trial of a vaccine designed entirely by artificial intelligence. The experimental shot targets shared features across families of viruses such as coronaviruses and aims to provide protection that remains effective even as pathogens mutate.

The trial ran from December 2021 to September 2023 and enrolled 39 volunteers. Participants received up to four doses delivered by a high-speed liquid jet that pushes the antigen into the skin without a needle. Researchers reported the vaccine was well tolerated and produced no significant safety concerns.

How the AI-Designed Component Works Scientists compiled all available genetic sequence data for Sarbeco coronaviruses collected through global surveillance programs. Machine learning then generated a single protein, called a super-antigen, that mimics features common to multiple viruses rather than matching one specific strain.

This approach is intended to train the immune system to recognize and respond to a broad range of related pathogens. The same method could be applied to other virus groups such as Ebola, according to the researchers.

Researchers said these properties could improve access in low- and middle-income countries and speed distribution during outbreaks. The needle-free delivery system also removes the need for sharps disposal and may increase acceptance in settings where injections are a barrier.

The study will measure whether the immune responses generated are strong and broadly protective.

“We’ve converted vaccine development from being reactive to being future proof." — Professor Jonathan Heeney, University of Cambridge. The trial’s chief investigator, Professor Saul Faust of the University of Southampton, noted that current vaccines often lag behind evolving viruses. He said the new design aims to break that cycle by preparing protection against both known and yet-to-emerge threats.”